Inhibikase Therapeutics replaces auditor CohnReznick with Deloitte - IKT News | RalliesInhibikase Therapeutics replaces auditor CohnReznick with Deloitte
I
IKT• Auditor change effective for fiscal 2026
- Inhibikase Therapeutics replaced auditor CohnReznick with Deloitte as independent accountant for fiscal 2026, effective Aug. 21, 2026.
- CohnReznick’s audit opinions for 2025 and 2024 were clean, with no adverse opinion, disclaimer, or scope or accounting qualifications.
- No accounting or auditing disagreements were reported with CohnReznick through its dismissal date.
- A previously disclosed material weakness in internal controls was flagged in 2024, then remediated by prior management in 2024.
AAT
•
